ReviewJournal of pharmaceutical analysis2024
New advances of adiponectin in regulating obesity and related metabolic syndromes.
Review in Journal of pharmaceutical analysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.Diabetes, obesity & metabolism · 2026Trial
- The adiponectin/leptin ratio as a biomarker of adiposopathy and visceral adipose tissue accumulation: sex-specific mechanisms.Adipocyte · 2026Article
- Role of adiponectin in gestational diabetes mellitus: advances in mechanistic insights and early predictive potential.Adipocyte · 2026Review
- Review
- Evaluation of Serum Irisin, Leptin, Adiponectin, Resistin, and Galectin-3 Levels and Their Relationship with Ultrasonographic Subcutaneous Fat Thickness in Patients with Lipedema.Aesthetic plastic surgery · 2026Article
- Growth differentiation factor-15 and body roundness index in relation to cardiometabolic risk in young adults with obesity.Endocrine · 2026Article
- The mediating effects of home environment on the relationship between maternal BMI and childhood obesity: Findings from the ECHO-wide cohort.European journal of pediatrics · 2026Article
- Adiponectin preserves follicles through ADIPOR1/ADIPOR2-driven fatty acid metabolism.Molecular metabolism · 2026Article
- Lactoferrin Deficiency During Lactation Causes Adult Obesity-Related Metabolic Disease Through Persistent Adipose Dysfunction Driven by Impaired Adipocyte Development.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Adipose Tissue-Central Nervous System Axis in Obesity: Molecular Mechanisms, Inflammation, and Nutritional and Technological Implications.Metabolites · 2026Review
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Myovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.Circulation research · 2026Review
- A combined model integrating adiponectin and anthropometric indices for the identification of insulin resistance in patients with type 2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Nutrition Across the Life Course and Risk of Young-Onset Breast Cancer: Mechanisms, Evidence, and Prevention Opportunities.Nutrients · 2026Review
- Exercise Intensity and Circulating Exerkine Responses: A Narrative Review of Selected Molecules.Biomolecules · 2026Review
- Targeting perivascular adipose tissue in vascular aging: innovative translational strategies for disease prevention and monitoring.Apoptosis : an international journal on programmed cell death · 2026Review
- Joint association of atherogenic index of plasma (AIP) and body roundness index (BRI) with cardiometabolic multimorbidity in adults in Guangzhou, China.Cardiovascular diabetology · 2026Article
- Rewiring Adipocyte Plasticity: The Redox-Mitochondrial Axis as a Driver of Beige Fat Immunometabolism and Adipose Inflammation.Biomolecules · 2026Review
- Deubiquitinase USP17 negatively regulates 3T3-L1 adipocyte differentiation via HDAC1.Genes & diseases · 2026Article
- Adiponectin and aging: Mechanistic insights, clinical paradox, and therapeutic horizons.Ageing research reviews · 2026Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and related metabolic syndromes have been recognized as important disease risks, in which the role of adipokines cannot be ignored. Adiponectin (ADP) is one of the key adipokines with various beneficial effects, including improving glucose and lipid metabolism, enhancing insulin sensitivity, reducing oxidative stress and inflammation, promoting ceramides degradation, and stimulating adipose tissue vascularity. Based on those, it can serve as a positive regulator in many metabolic syndromes, such as type 2 diabetes (T2D), cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), sarcopenia, neurodegenerative diseases, and certain cancers. Therefore, a promising therapeutic approach for treating various metabolic diseases may involve elevating ADP levels or activating ADP receptors. The modulation of ADP genes, multimerization, and secretion covers the main processes of ADP generation, providing a comprehensive orientation for the development of more appropriate therapeutic strategies. In order to have a deeper understanding of ADP, this paper will provide an all-encompassing review of ADP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.